28 research outputs found
Survival curves depicting cancer-specific survival in the radical prostatectomy (RP) and external beam radiotherapy (EBRT) groups, in (A) all (<i>P</i> = 0.0010), (B) low-risk (<i>P</i> <0.0001), (C) intermediate-risk (<i>P</i> = 0.1820), and (D) high-risk patients (<i>P</i> = 0.0233), respectively.
<p>Each <i>P</i>-value indicates the result of log-rank test.</p
Survival curves depicting biochemical recurrence-free survival in the radical prostatectomy (RP) and external beam radiotherapy (EBRT) groups, in (A) all (<i>P</i> <0.0001), (B) low-risk (<i>P</i> = 0.0230), (C) intermediate-risk (<i>P</i> = 0.0030), and (D) high-risk patients (<i>P</i> = 0.0025), respectively.
<p>Each <i>P</i>-value indicates the result of log-rank test.</p
Other-cause mortality in the radical prostatectomy (RP) and external beam radiotherapy (EBRT) groups (log-rank test, <i>P</i> = 0.0001).
<p>Other-cause mortality in the radical prostatectomy (RP) and external beam radiotherapy (EBRT) groups (log-rank test, <i>P</i> = 0.0001).</p
Baseline patient characteristics of the RP and EBRT groups in all patients (<i>n</i> = 891).
<p>RP, radical prostatectomy; EBRT, external beam radiotherapy; IQR, interquartile range; PSA, prostate-specific antigen; GS, Gleason score; ADT, androgen deprivation therapy.</p><p>*Statistically significant</p><p><sup>a</sup>Student’s <i>t</i>-test</p><p><sup>b</sup>Chi-square test.</p><p>Baseline patient characteristics of the RP and EBRT groups in all patients (<i>n</i> = 891).</p
Flow chart representing the study selection process.
<p>Flow chart representing the study selection process.</p
Baseline patient characteristics of the RP and EBRT groups in high-risk patients (<i>n</i> = 336).
<p>RP, radical prostatectomy; EBRT, external beam radiotherapy; IQR, interquartile range; PSA, prostate-specific antigen; GS, Gleason score; ADT, androgen deprivation therapy.</p><p>*Statistically significant;</p><p><sup>a</sup>Student’s <i>t</i>-test;</p><p><sup>b</sup>Chi-square test</p><p>Baseline patient characteristics of the RP and EBRT groups in high-risk patients (<i>n</i> = 336).</p
Benefit of adjuvant immunotherapy in renal cell carcinoma: A myth or a reality?
<div><p>Background</p><p>The benefit of adjuvant immunotherapy after nephrectomy in renal cell carcinoma (RCC) is controversial. The present study aimed to examine the possible benefit of adjuvant immunotherapy in various clinical settings.</p><p>Methods</p><p>We retrospectively reviewed 436 patients with pT1-3N0-2M0 RCC who underwent radical or partial nephrectomy with curative intent at our institution between 1981 and 2009. Of them, 98 (22.5%) patients received adjuvant interferon-α (IFN-α) after surgery (adjuvant IFN-α group), while 338 (77.5%) did not (control group). The primary endpoint was cancer-specific survival (CSS). Univariate and multivariate analyses were conducted using log-rank tests and Cox proportional hazards models, respectively.</p><p>Results</p><p>Fifty-two (11.9%) patients died from RCC with a median follow-up period of 96 months. Preliminary univariate analyses comparing CSS among treatment groups in each TNM setting revealed that CSS in the control group was equal or superior to that in the adjuvant IFN-α group in earlier stages, while the opposite trend was observed in more advanced stages. We evaluated the TNM cutoffs and demonstrated maximized benefit of adjuvant IFN-α in patients with pT2b-3cN0 (<i>P</i> = 0.0240). In multivariate analysis, ≥pT3 and pN1-2 were independent predictors for poor CSS in all patients. In the subgroups with ≥pT2 disease (<i>n</i> = 123), pN1-2 and no adjuvant treatment were significant poor prognostic factors.</p><p>Conclusions</p><p>Adjuvant immunotherapy after nephrectomy may be beneficial in pT2b-3cN0 RCC. Careful consideration is, however, required for interpretation of this observational study because of its selection bias and adverse effects of IFN-α.</p></div
Additional file 1: Table S1. of Toremifene, a selective estrogen receptor modulator, significantly improved biochemical recurrence in bone metastatic prostate cancer: a randomized controlled phase II a trial
CONSORT 2010 checklist of information to include when reporting a cluster randomised trial. (DOCX 30 kb
Additional file 1: Figure S1. of Prognostic value of CD66b positive tumor-infiltrating neutrophils in testicular germ cell tumor
Receiver operating characteristic (ROC) curve analysis was performed to determine the cutoff value of TIN counts by using the 0, 1 criterion. In the present study, overall survival status had the largest AUC (0.80217), and we selected cutoff value determined by overall survival status. Cutoff value was selected from the point which was closest to both maximum sensitivity and specificity (21.6 counts/microscopic field). Therefore, high and low TIN density was defined as counts ≤ 21 and counts > 21, respectively. (TIF 217 kb
Univariate and multivariate analyses of cancer-specific survival in patients with ≥pT2 disease (<i>n</i> = 123).
<p>Univariate and multivariate analyses of cancer-specific survival in patients with ≥pT2 disease (<i>n</i> = 123).</p